昭衍新藥(603127.SH)2020年度淨利潤預增約69.9%到80.3%
格隆匯 1 月 19日丨昭衍新藥(603127.SH)公佈,預計2020年度實現歸屬於上市公司股東的淨利潤約人民幣3.03億元到3.22億元之間,與上年同期的財務報表數據相比,將增加約人民幣1.246億元到1.433億元,同比增加約69.9%到80.3%;預計2020年度歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期的財務報表數據相比,將增加約人民幣1.2億元到1.387億元,同比增加約77.5%到89.6%。
預計2020年度實現歸屬於上市公司股東的淨利潤與上年同期經重述後的財務報表數據相比,預計增加約人民幣1.16億元到1.35億元,同比增加約62.2%到72.2%;歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期經重述後的財務報表數據相比,將增加約人民幣1.12億元到1.30億元,同比增加約68.4%到79.8%。
本期業績預增的主要原因:(一)主營業務影響。隨着國內藥物研發投入力度的增加,醫藥研發機構紛紛加碼創新藥物的研發,2020年CRO行業景氣度持續向好,公司承接訂單繼續保持高速增長;同時,公司不斷提升經營管理水平,設施利用率得到進一步提升,訂單執行和完成情況均處於較高水平,規模化效應凸顯。
(二)非經營性損益的影響。主要受以前年度和當年收到的政府補助本期按照企業會計準則轉入當期損益約2772.31萬元以及當年確認理財收益589.58萬元。
(三)會計政策變更影響。公司本年度對生物資產的後續計量模式由成本模式計量變更為公允價值模式計量,所以相應調整可比期間的信息。關於會計政策變更內容詳見公司於2021年1月20日在上海證券交易所網站披露的《關於會計政策變更的公吿》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.